Tarsus Pharmaceuticals Q3 2026 Results: Net Loss of $668M, Loss Widens
Tarsus Pharmaceuticals reported a significant net loss of $693.9 million for the nine months ended September 30, 2026, primarily driven by $632.2 million in acquired in-process research and development expenses from the acquisitions of iRenix and Alkeus. Despite the net loss, total revenues grew to $530.5 million, up from $299.7 million in the prior year, fueled by strong product sales.
- Key figure
- Net loss $668M